Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the challenges and advancements in treating acute myeloid leukemia (AML) in patients who are unfit for intensive…
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, discusses a study evaluating the efficacy of combining venetoclax with hypomethylating agents in treating patients with acute myeloid leukemia…
NEW YORK (Reuters Health) – For patients with primary cutaneous melanoma, targeted high-resolution ultrasound should not be used as a substitute for excisional sentinal lymph node biopsy, new…
NEW YORK (Reuters Health) – In detecting prostate cancer, no single prostate specific antigen (PSA) cut-off value achieves the likelihood ratios usually required of a screening test, according…
NEW YORK (Reuters Health) – New research indicates that over half of men who choose watchful waiting as the initial strategy for prostate cancer require no treatment on…
NEW YORK (Reuters Health) – In premenopausal women with breast cancer, adjuvant tamoxifen treatment significantly reduces the risk of contralateral breast cancer, according to results of a Swedish…
NEW YORK (Reuters Health) – Treatment with estrogen plus progestin does not seem to increase the risk of lung cancer per se, but it may increase the odds…
NEW YORK (Reuters Health) – Postmenopausal breast cancer patients taking aromatase inhibitors have increased risks for carpal tunnel syndrome and new or worsening arthralgia, two studies published online…
NEW YORK (Reuters Health) – The combination of pentoxifylline and vitamin E prevented radiation-induced lymphedema among breast cancer patients in a phase II trial in Sweden. The finding…
NEW YORK (Reuters Health) – New research indicates that the outcomes of localized prostate cancer following conservative management have improved in the last few decades. According to the…
NEW YORK (Reuters Health) – Particle beam radiation has been available since 1954, but a systematic literature review has failed to turn up statistically or clinically significant differences…
NEW YORK (Reuters Health) – Findings from a systematic review indicate that while tamoxifen, raloxifene, and tibolone all reduce the risk of primary breast cancer, the drugs differ…
